DK3773689T3 - Antigene peptider til forebyggelse og behandling af kræft - Google Patents
Antigene peptider til forebyggelse og behandling af kræft Download PDFInfo
- Publication number
- DK3773689T3 DK3773689T3 DK19716176.3T DK19716176T DK3773689T3 DK 3773689 T3 DK3773689 T3 DK 3773689T3 DK 19716176 T DK19716176 T DK 19716176T DK 3773689 T3 DK3773689 T3 DK 3773689T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- prevention
- treatment
- antigenic peptides
- antigenic
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305444 | 2018-04-11 | ||
| EP2018077512 | 2018-10-09 | ||
| PCT/EP2019/059329 WO2019197567A2 (en) | 2018-04-11 | 2019-04-11 | Antigenic peptides for prevention and treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3773689T3 true DK3773689T3 (da) | 2023-01-16 |
| DK3773689T5 DK3773689T5 (da) | 2024-08-19 |
Family
ID=66092357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19716176.3T DK3773689T5 (da) | 2018-04-11 | 2019-04-11 | Antigene peptider til forebyggelse og behandling af kræft |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12016910B2 (da) |
| EP (2) | EP3773689B1 (da) |
| JP (2) | JP7384819B2 (da) |
| CN (1) | CN112118863A (da) |
| AU (1) | AU2019253217A1 (da) |
| BR (1) | BR112020020780A2 (da) |
| CA (1) | CA3094262A1 (da) |
| DK (1) | DK3773689T5 (da) |
| ES (1) | ES2935702T3 (da) |
| FI (1) | FI3773689T3 (da) |
| HR (1) | HRP20230007T1 (da) |
| HU (1) | HUE060791T2 (da) |
| LT (1) | LT3773689T (da) |
| MX (2) | MX2020010701A (da) |
| PL (1) | PL3773689T3 (da) |
| RS (1) | RS63873B1 (da) |
| SI (1) | SI3773689T1 (da) |
| WO (1) | WO2019197567A2 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| US11478537B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| AU2020384926A1 (en) * | 2019-11-15 | 2022-04-28 | Enterome S.A. | Antigenic peptides for prevention and treatment of B-cell malignancy |
| CN111197040B (zh) * | 2020-01-21 | 2023-08-08 | 福建亿彤生物科技有限公司 | 壳多糖酶3样蛋白1（chi3l1）抗原表位肽、抗原、抗体、用途及试剂盒 |
| WO2023187127A1 (en) * | 2022-03-31 | 2023-10-05 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
| IT202200006785A1 (it) * | 2022-04-06 | 2023-10-06 | Istituto Naz Tumori Irccs Fondazione G Pascale | Analoghi di antigeni tumorali da microbiota e usi relativi |
| WO2024025397A1 (ko) * | 2022-07-29 | 2024-02-01 | 주식회사 엘지화학 | 항원 전달용 재조합 융합 단백질 및 이의 이용 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| WO2001000225A1 (en) | 1999-06-29 | 2001-01-04 | Epimmune Inc. | Hla binding peptides and their uses |
| US5550214A (en) | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1163000B1 (en) | 1999-03-19 | 2008-02-27 | GlaxoSmithKline Biologicals S.A. | Vaccine against antigens from bacteriae |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| JP2003524016A (ja) | 2000-02-23 | 2003-08-12 | エピミューン， インコーポレイテッド | Ｈｌａ結合ペプチドおよびそれらの用途 |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| EP1496923A4 (en) | 2002-03-22 | 2005-10-19 | Penn State Res Found | IMMUNOTHERAPY AGAINST CANCER |
| US20060079453A1 (en) | 2002-10-03 | 2006-04-13 | John Sidney | Hla binding peptides and their uses |
| CN1954217B (zh) | 2004-02-06 | 2013-05-08 | 国立健康与医学研究所 | 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途 |
| WO2006034334A2 (en) | 2004-09-21 | 2006-03-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| JP2010512402A (ja) | 2006-12-11 | 2010-04-22 | ワイス エルエルシー | Ｉｌ−１３関連障害を治療するための方法および組成物ならびにその治療をモニター観察するための方法 |
| MX2010002002A (es) * | 2007-08-20 | 2010-03-11 | Oncotherapy Science Inc | Peptido foxm1 y agente medicinal que lo contiene. |
| PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| WO2010018136A1 (en) | 2008-08-12 | 2010-02-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Minigene comprising htpa signal peptide, t-cell epitopes, e. coli ltb and furin sensitive linkers |
| PL2172211T3 (pl) * | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
| US20110033389A1 (en) | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| EP2500350B1 (en) * | 2009-11-03 | 2018-08-15 | Korea University Research And Business Foundation | Composite of a protein comprising zinc oxide-bonding peptides and zinc oxide nanoparticles, and use thereof |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| US9314516B2 (en) | 2010-05-04 | 2016-04-19 | Cassian Yee | Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses |
| EP4159226A1 (en) | 2010-08-24 | 2023-04-05 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
| WO2013101690A1 (en) | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| JP6502247B2 (ja) | 2012-03-19 | 2019-04-17 | ステムライン セラピューティクス，インコーポレーテッド | 癌の状態を治療及びモニタリングする方法 |
| US9428813B2 (en) | 2012-03-26 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | DNA methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms |
| JP6189415B2 (ja) | 2012-04-02 | 2017-08-30 | モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． | 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド |
| HUE056350T2 (hu) | 2012-05-16 | 2022-02-28 | Stemline Therapeutics Inc | Rákos õssejt célzott rák elleni vakcinák |
| US20140141044A1 (en) | 2012-11-12 | 2014-05-22 | Dana-Farber Cancer Institute, Inc. | Cord Colitis Syndrome Pathogen |
| US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
| NZ708727A (en) | 2012-12-06 | 2019-09-27 | Victoria Link Ltd | Conjugate compounds |
| GB201315946D0 (en) * | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| AU2015271324B2 (en) * | 2014-06-06 | 2019-09-12 | Herlev Hospital | Determining antigen recognition through barcoding of MHC multimers |
| WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| CN108026513A (zh) | 2015-03-31 | 2018-05-11 | 新加坡科技研究局 | 树突状细胞的抗原加载的方法和疫苗 |
| EP3464630A1 (en) | 2016-05-23 | 2019-04-10 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Methods of diagnosing cancer using cancer testis antigens |
| US11478537B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| WO2018065628A2 (en) | 2016-10-07 | 2018-04-12 | Enterome | Microbiota sequence variants of tumor-related antigenic epitopes |
| AU2018348432A1 (en) | 2017-10-09 | 2020-04-02 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| US20210106652A1 (en) | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| MX2022004598A (es) | 2019-10-16 | 2022-09-23 | Enterome S A | Compuestos inmunogenicos para el tratamiento del cancer suprarrenal. |
| AU2020384926A1 (en) | 2019-11-15 | 2022-04-28 | Enterome S.A. | Antigenic peptides for prevention and treatment of B-cell malignancy |
-
2019
- 2019-04-11 CN CN201980032574.8A patent/CN112118863A/zh active Pending
- 2019-04-11 JP JP2020555892A patent/JP7384819B2/ja active Active
- 2019-04-11 WO PCT/EP2019/059329 patent/WO2019197567A2/en unknown
- 2019-04-11 US US17/043,192 patent/US12016910B2/en active Active
- 2019-04-11 RS RS20230005A patent/RS63873B1/sr unknown
- 2019-04-11 HR HRP20230007TT patent/HRP20230007T1/hr unknown
- 2019-04-11 EP EP19716176.3A patent/EP3773689B1/en active Active
- 2019-04-11 CA CA3094262A patent/CA3094262A1/en active Pending
- 2019-04-11 PL PL19716176.3T patent/PL3773689T3/pl unknown
- 2019-04-11 MX MX2020010701A patent/MX2020010701A/es unknown
- 2019-04-11 BR BR112020020780-2A patent/BR112020020780A2/pt unknown
- 2019-04-11 FI FIEP19716176.3T patent/FI3773689T3/fi active
- 2019-04-11 AU AU2019253217A patent/AU2019253217A1/en active Pending
- 2019-04-11 DK DK19716176.3T patent/DK3773689T5/da active
- 2019-04-11 EP EP22201142.1A patent/EP4169528A1/en active Pending
- 2019-04-11 SI SI201930437T patent/SI3773689T1/sl unknown
- 2019-04-11 LT LTEPPCT/EP2019/059329T patent/LT3773689T/lt unknown
- 2019-04-11 HU HUE19716176A patent/HUE060791T2/hu unknown
- 2019-04-11 ES ES19716176T patent/ES2935702T3/es active Active
-
2020
- 2020-10-09 MX MX2023014457A patent/MX2023014457A/es unknown
-
2023
- 2023-11-09 JP JP2023191203A patent/JP2024016203A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019253217A1 (en) | 2020-10-15 |
| WO2019197567A3 (en) | 2019-11-28 |
| EP4169528A1 (en) | 2023-04-26 |
| EP3773689A2 (en) | 2021-02-17 |
| WO2019197567A2 (en) | 2019-10-17 |
| SI3773689T1 (sl) | 2023-02-28 |
| CN112118863A (zh) | 2020-12-22 |
| HUE060791T2 (hu) | 2023-04-28 |
| PL3773689T3 (pl) | 2023-03-13 |
| ES2935702T3 (es) | 2023-03-09 |
| HRP20230007T1 (hr) | 2023-03-03 |
| EP3773689B1 (en) | 2022-11-09 |
| LT3773689T (lt) | 2023-01-25 |
| CA3094262A1 (en) | 2019-10-17 |
| JP7384819B2 (ja) | 2023-11-21 |
| FI3773689T3 (fi) | 2023-01-31 |
| DK3773689T5 (da) | 2024-08-19 |
| US12016910B2 (en) | 2024-06-25 |
| MX2020010701A (es) | 2021-01-20 |
| JP2021520818A (ja) | 2021-08-26 |
| RS63873B1 (sr) | 2023-02-28 |
| BR112020020780A2 (pt) | 2021-03-02 |
| US20210113678A1 (en) | 2021-04-22 |
| JP2024016203A (ja) | 2024-02-06 |
| MX2023014457A (es) | 2023-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3773689T5 (da) | Antigene peptider til forebyggelse og behandling af kræft | |
| DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3455259T3 (da) | Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling | |
| DK3331915T3 (da) | Immun-checkpoint-inhibitorer til anvendelse til behandling af blodbårne cancere | |
| DK3471755T3 (da) | Pegyleret svineinterferon og fremgangsmåder til anvendelse deraf | |
| DK3518933T3 (da) | Fremgangsmåder til behandling af uterusfibromer og endometriose | |
| DK4021487T5 (da) | Antigene peptider til forebyggelse og behandling af b-celle malignitet | |
| DK3584252T3 (da) | Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3504210T3 (da) | 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion | |
| DK3426777T3 (da) | Kombinationsvektorer og fremgangsmåder til behandling af cancer | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| ZA202007649B (en) | Virus and antigen purification and conjugation | |
| DK3653644T5 (da) | Monoklonale antistoffer mod vækst- og differentieringsfaktor 15 (gdf-15) og anvendelser deraf til behandling af kræftrelateret kakeksi og kræft | |
| DK3319985T3 (da) | Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod øsofaguscancer og andre cancere | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3273986T3 (da) | Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer | |
| DK3310190T3 (da) | Sammensætning til behandling af kød og anvendelse af denne | |
| DK3790879T3 (da) | Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft | |
| DK3293201T3 (da) | Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3720879T3 (da) | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer | |
| DK3773738T3 (da) | Antistof-lægemiddelkonjugater og anvendelser deraf til behandling af cancer | |
| DK3778592T3 (da) | PSMA-målrettet radiolægemiddel til diagnosticering og behandling af prostatacancer | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme |